领航医药生物科技(00399.HK) 表示，拟扩充业务至区块链技术，进军数码创新行业。
集团将启动研究开发项目，集中于区块链的相关基础设施及共通关键技术，目标为提升多类数码及商业交易的透明度、安全性及效率。此计划乃为将集团定位在创新技术应用的前端，并开发新业务模型及收益来源。集团将成立专门技术团队，凭借与领先区块链平台及学术机构的合作伙伴关系，带头进行研究及开发。
为支持该计划，公司可能透过不同方式筹集资金，包括配售，以及向股东或财务机构借贷。公司亦可能扩大董事会及高级管理层团队以纳入合资格人士以确保新项目的成功。(ha/da)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.